Kristopher Lybarger, DO
Gynecologic Oncology · Kansas City, MONPI 1013172022
Payments from drug & device makers
Across 1,195 payments — averaging $1504.29 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$414K
- Tesaro, Inc.$378K
- Davol Inc.$343K
- Karyopharm Therapeutics Inc.$245K
- Incyte Corporation$127K
- Genmab U.S., Inc.$106K
- plus $185K from 32 others
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 181 | $414,498 |
| Tesaro, Inc. | 170 | $378,269 |
| Davol Inc. | 325 | $342,921 |
| Karyopharm Therapeutics Inc. | 141 | $244,795 |
| Incyte Corporation | 20 | $126,678 |
| Genmab U.S., Inc. | 29 | $105,956 |
| Eli Lilly | 7 | $49,617 |
| Clovis Oncology, Inc. | 39 | $40,965 |
| Seagen Inc. | 26 | $24,462 |
| AstraZeneca | 22 | $13,713 |
| Pfizer | 3 | $12,568 |
| Immunogen, Inc. | 23 | $10,828 |
| Myriad Genetic Laboratories, Inc. | 17 | $9,227 |
| Medical Device Business Services, Inc. | 11 | $8,254 |
| Intuitive Surgical | 24 | $6,454 |
| Johnson & Johnson(3 entities) | 35 | $2,273 |
| Janssen Research & Development, LLC | 3 | $2,183 |
| BD | 12 | $1,185 |
| Merck | 52 | $1,127 |
| AbbVie | 19 | $595 |
| Dysis Medical, Inc. | 4 | $268 |
| Eisai Inc. | 12 | $264 |
| Genentech, Inc. | 1 | $147 |
| Integra Lifesciences Corporation | 2 | $52 |
| Olympus America Inc. | 2 | $38 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $37 |
| Verastem, Inc. | 1 | $33 |
| Kyowa Kirin, Inc. | 2 | $31 |
| Teleflex LLC | 1 | $23 |
| Gilead | 1 | $22 |
| Daiichi Sankyo Inc. | 1 | $21 |
| Taiho Oncology, Inc. | 1 | $20 |
| Ipsen Biopharmaceuticals, Inc | 1 | $20 |
| Novartis | 1 | $18 |
| Sanofi | 1 | $18 |
| G1 Therapeutics, Inc. | 1 | $17 |
| Axonics, Inc. | 1 | $14 |
| Therapeuticsmd, Inc. | 1 | $11 |
How this compares
$1,797,622 in reported general payments places this provider in the 90th percentile of 38 gynecologic oncology providers in Missouri.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other gynecologic oncology in Kansas City
- Michelle RowlandKansas City$35K
- Verda HicksKansas City$11K
- Jason KnightKansas City$1K
- Susan Duyar-AyerdiKansas City$550
- Nora BadinerKansas City$152
- John WeedKansas City$86
- David MutchSaint Louis$4.1M
- Premal ThakerSaint Louis$2.6M
- Matthew PowellSaint Louis$1.1M
- Erin TullerColumbia$955K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.